Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 SEK | +10.54% | +18.30% | -58.22% |
May. 30 | Oncopeptides Issues Warrants Under Loan Deal with European Investment Bank | MT |
May. 30 | Transcript : Oncopeptides AB, Q1 2024 Earnings Call, May 30, 2024 |
Sales 2024 * | 82.38M 7.83M | Sales 2025 * | 196M 18.6M | Capitalization | 702M 66.69M |
---|---|---|---|---|---|
Net income 2024 * | -244M -23.18M | Net income 2025 * | -174M -16.53M | EV / Sales 2024 * | 6.84 x |
Net cash position 2024 * | 138M 13.14M | Net Debt 2025 * | 62.58M 5.95M | EV / Sales 2025 * | 3.91 x |
P/E ratio 2024 * |
-2.1
x | P/E ratio 2025 * |
-3.07
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.37% |
Latest transcript on Oncopeptides AB
1 day | +10.54% | ||
1 week | +18.30% | ||
1 month | +9.97% | ||
3 months | -33.69% | ||
6 months | -61.34% | ||
Current year | -58.22% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 3.2 | +10.54% | 3,648,081 |
24-05-30 | 2.895 | +6.83% | 8,189,789 |
24-05-29 | 2.71 | -4.91% | 1,601,188 |
24-05-28 | 2.85 | +5.95% | 2,525,880 |
24-05-27 | 2.69 | -0.55% | 1,583,667 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.22% | 59.96M | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- ONCO Stock